ArticleBrain : a journal of neurology2020
Plasma p-tau217: from 'new kid' to most promising candidate for Alzheimer's disease blood test.
Article in Brain : a journal of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies.The journal of prevention of Alzheimer's disease · 2024Trial
- Predictive value of plasma p-tau217 for Alzheimer's dementia compared to other blood-based biomarkers.EMBO molecular medicine · 2026Article
- Multimodal Integration of Gait Dysfunction, Amyloid PET, and Plasma Biomarkers for Differentiating Etiological Subtypes in Mild Cognitive Impairment.CNS neuroscience & therapeutics · 2026Article
- An Immuno-Infrared Sensor Detects Preclinical Alzheimer's and Parkinson's Disease by Protein Misfolding.The journal of physical chemistry. B · 2026Review
- Biomarkers in Disease Diagnosis and Monitoring: Insights into Clinical Applications and Mass Spectrometry-based Detection.Applied biochemistry and biotechnology · 2026Review
- Plasma p-tau217 and p-tau217/AβScientific reports · 2025Article
- Prospective evaluation of plasma pTauAlzheimer's research & therapy · 2025Article
- Diagnostic performance of plasma p-tau217 in a memory clinic cohort using the Lumipulse automated platform.Alzheimer's research & therapy · 2025Article
- The early diagnosis of Alzheimer's disease: Blood-based panel biomarker discovery by proteomics and metabolomics.CNS neuroscience & therapeutics · 2024Review
- Performance of plasma p-tau217 for the detection of amyloid-β positivity in a memory clinic cohort using an electrochemiluminescence immunoassay.Alzheimer's research & therapy · 2024Article
- Diagnostic performance of plasma pTauAlzheimer's research & therapy · 2024Article
- Evaluating p-tau217 and p-tau231 as Biomarkers for Early Diagnosis and Differentiation of Alzheimer's Disease: A Narrative Review.Biomedicines · 2024Review
- Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- A novel ultrasensitive assay for plasma p-tau217: Performance in individuals with subjective cognitive decline and early Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Longitudinal Phospho-tau217 Predicts Amyloid Positron Emission Tomography in Asymptomatic Alzheimer's Disease.The journal of prevention of Alzheimer's disease · 2024Observational
- Diagnostic performance of plasma pTau 217, pTau 181, Aβ 1-42 and Aβ 1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease.Research square · 2023Article
- Modern Methods of Diagnostics and Treatment of Neurodegenerative Diseases and Depression.Diagnostics (Basel, Switzerland) · 2023Review
- Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Review
- Mass spectrometry-based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids.Journal of neurochemistry · 2021Review
- Refining Alzheimer's disease biological diagnosis with plasma biomarkers: Resolving p-tau217 "gray zone" with p-tau181 integration.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.